“Recent media scrutiny into the backgrounds of Investigators and other HCPs has created a critical challenge for Life Sciences companies looking to encourage clinical studies and maintain compliance. Finding out that a funded Investigator has received an FDA warning would be a difficult surprise. Even worse would be finding out in the news media,” said Jim Zuffoletti, President of OpenQ. “We developed Expert Screening and integrated into OpenIIS, our leading offering for managing IIS programs, to make it simple and economical for companies to avoid this issue and know that the investigators they collaborate with possess the clinical experience and the discipline-free records the industry values.”
About OpenQ:
Based in Charlottesville, Virginia, OpenQ helps Life Sciences companies manage compliant business processes in their Marketing and Medical Affairs organizations. OpenQ offers award-winning solutions for compliant business processes focused on KOL Management, Medical Affairs Programs, Study Management & Grant Funding, and Speaker Programs. OpenQ’s solutions currently support compliance initiatives at 8 of the Top 10 Pharmaceutical and 3 of the Top 5 Medical Device Companies. For more information, visit www.openq.com.
To view OpenQ’s recent web seminar on managing compliant Investigator Sponsored Trials programs please got to - http://www.openq.com/IISWebinar/